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Abstract Detection of activating EGFR mutations in
NSCLC is the prerequisite for individualised therapy with
receptor tyrosine kinase inhibitors (TKI). In contrast, mutant
downstream effector KRAS is associated with TKI resis-
tance. Accordingly, EGFR mutation status is routinely ex-
amined in NSCLC specimens, but the employed methods
may have a dramatic impact on the interpretation of results
and, consequently, therapeutic decisions. Specimens with
low tumour cell content are at particular risk for false-
negative EGFR mutation reporting by sequencing with
Sanger chemistry. To improve reliability of detecting clini-
cally relevant mutant variants of EGFR and KRAS, we took
full advantage of 454 deep sequencing and developed a two-
step amplification protocol for the analysis of EGFR exons
18–21 and KRAS exons 2 and 3. We systematically
addressed the sensitivity, reproducibility and specificity of
the developed assay. Mutations could be reliably identified
down to an allele frequency of 0.2–1.5 %, as opposed to 10–
20 % detection limit of Sanger sequencing. High reproduc-
ibility (0–2.1 % variant frequency) and very low back-
ground level (0.4–0.8 % frequency) further complement
the reliability of this assay. Notably, re-evaluation of 16
NSCLC samples with low tumour cell content ≤40 % and
EGFR wild type status according to Sanger sequencing
revealed clinically relevant EGFR mutations at allele fre-
quencies of 0.9–10 % in seven cases. In summary, this novel
two-step amplification protocol with 454 deep sequencing is
superior to Sanger sequencing with significantly increased
sensitivity, enabling reliable analysis of EGFR and KRAS in
NSCLC samples independent of the tumour cell content.
Keywords NSCLC . EGFR . KRAS . 454 Deep
sequencing . Sensitivity
Introduction
The observation of activating mutations in the tyrosine
kinase domain of the epidermal growth factor receptor
(EGFR) gene in ~10 % of all non-small cell lung cancers
(NSCLC) has opened the possibility of targeted therapy with
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receptor tyrosine kinase inhibitors (TKIs) directed against
mutant EGFR [1–3]. Since clinical phase III trials have dem-
onstrated the benefit of TKI application for patients whose
tumours harbour activating EGFR mutations [4, 5], mutation
analysis of EGFR is suggested to be routinely performed in
NSCLC specimens [6]. In contrast, activating mutations in the
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
(KRAS) gene, a member of the Ras family of small
GTPases, were present in 27 % of NSCLCs (all adenocarci-
nomas) in a recently published sequencing study, and these
two mutations occur mutually exclusive [7]. Importantly, mu-
tant KRAS is located downstream in the signalling cascade of
EGFR and consequently associated with resistance to TKI
therapy [8]. Therefore, mutation analysis of both EGFR and
KRAS is vital for individualised therapeutic decisions.
Several issues exist, however, which hamper employ-
ment of EGFR mutation detection as a reliable diagnostic
tool. First, significant discrepancy of EGFR mutation fre-
quencies (6.8–25.9 %) and, hence, reporting of EGFR mu-
tation status has been revealed in a recent inter-laboratory
comparison in routinely processed NSCLC samples [9].
This raises the question of methodical problems in this
therapeutically relevant testing. Second, in patients with
extensive disease (stage IV), only small biopsies or cytolog-
ical specimens are usually available with limited amount of
tumour cells. This may represent a serious obstacle for
mutation detection by routinely used sequencing with
Sanger chemistry. For example, a recent study has demon-
strated that ~30 % of NSCLC specimens in a large clinical
cohort contained less than 40 % tumour cells, the minimal
threshold needed for a reliable detection of EGFR mutations
using Sanger sequencing [10]. Other techniques frequently
used for detection of EGFRmutations are based on real-time
polymerase chain reaction (PCR) or pyrosequencing meth-
ods, with several commercially available kits. However,
while these methods have a better sensitivity of ~1–5 %
compared to Sanger sequencing, they will not identify 5–
10 % of the currently known EGFR mutations according to
their targeted approach. Collectively, these obstacles under-
score the need for alternative analytical principles that
achieve more accurate diagnostic results.
Next-generation sequencing techniques allow massively
parallel, or deep, sequencing of target regions with >1,000
reads per sample, thereby enabling detection of mutations at
much lower allele frequencies compared to Sanger sequenc-
ing. For example, 100 % of mutations were detected in
clinical responders to TKI therapy by 454 massively parallel
sequencing in a comparative study on 18 EGFR-mutated
NSCLC specimens, compared to only 89 % and 67 %
detection rates of mutations by pyrosequencing and Sanger
sequencing, respectively [11]. Despite an obviously lower
detection limit, no systematic analysis of the sensitivity,
reproducibility and specificity of 454 deep sequencing
regarding EGFR and KRAS mutations analysis has been
reported as yet. The unique possibility of detection of clin-
ically relevant mutations at very low allele frequencies in
the range of 1–10 % is associated with the risk of consider-
ing technical errors, which are introduced by DNA poly-
merase during amplicon library preparation or through base-
calling process as low-frequency variants [12]. Therefore, a
reliable threshold for background variants is desirable for
discrimination of noise and low-frequency variants.
Given the fact that clinical samples are almost exclusive-
ly available as formalin-fixed and paraffin-embedded
(FFPE) tissue specimens with often low-quality DNA, a
special procedure for amplicon library preparation is needed
to maximize the number of informative patient specimens
[13]. Since complex PCR primers are commonly used for
amplicon library preparation, which include 5´-overhangs of
adapter sequences for binding to the DNA capture beads and
barcode sequences for identity of different patient samples,
the percentage of efficiently amplified DNA samples may
be even lower. In the current study, we established a two-
step DNA amplification protocol with subsequent 454 deep
sequencing of EGFR and KRAS genes, which is capable of
successful amplification of FFPE NSCLC samples with low
DNA quality. We systematically evaluated its sensitivity,
reproducibility and specificity and provided reliable thresh-
olds for the lower detection limit of mutations (sensitivity),
variation of allele frequencies (reproducibility) and back-
ground levels (specificity). We next applied this assay to re-
evaluate clinical NSCLC samples with low tumour cell
content (≤40 %) that were EGFR wild type according to
conventional Sanger sequencing and identified EGFR muta-
tions in a significant proportion of these cases. In summary,
this study demonstrates the much higher sensitivity of the
developed 454 deep sequencing assay compared to Sanger
sequencing and strongly argues for its wide application in
routine molecular diagnostic analysis of clinical FFPE
NSCLC samples with low tumour content.
Materials and methods
Patient samples and cell culture
A total of 21 FFPE specimens were obtained from the
Institutes of Pathology in Erlangen, Gera and Ingolstadt
(Germany). The samples included cell block preparations
from cytological specimens (pleural effusions, n=4; fine nee-
dle aspirations, n=3), small endoscopic biopsies (n=11) and
resection specimens (n=3). Tumour specimens were
inspected by a pathologist to estimate the tumour cell content
and the histomorphological pattern.
The lung adenocarcinoma cell lines NCI-H1650 (EGFR
exon 19 deletion E746_A750del), NCI-H1975 (EGFR exon
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20 missense mutation T790M; EGFR exon 21 missense
mutation L858R), NCI-H460 (KRAS exon 3 missense mu-
tation Q61H), NCI-H1299 (EGFR and KRAS wildtype sta-
tus) as well as the colorectal adenocarcinoma cell line HCT-
116 (KRAS exon 2 missense mutation G13D) were pur-
chased from the American Type Culture Collection
(ATCC, USA). All the cells were grown in a medium con-
sisting of 90 % Roswell Park Memorial Institute Medium
1640 supplemented with 300 mg/L L-glutamine (Invitrogen,
Carlsbad, USA) and 10 % foetal bovine serum (Invitrogen).
DNA isolation and amplicon library preparation
DNA was extracted from the FFPE samples using the
QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden,
Germany) and from cell lines by DNeasy Blood & Tissue
Kit (Qiagen) as suggested by the manufacturer. The concen-
tration of DNA from the FFPE samples was measured in a
ND-1000 spectrophotometer (Thermo Scientif ic,
Wilmington, USA). Quantification of DNA from cell lines
for preparation of a dilution series of mutated DNA in wild-
type DNAwas performed by using the Quant-iT PicoGreen
dsDNA Assay kit (Invitrogen) and Synergy 2 Multi-Mode
Microplate Reader (Biotek, Winooski, USA). These control
DNA samples represented distinct percentages of mutant
variants: 50 %, 10 %, 7.5 %, 5 %, 2.5 %, 1 % and 0.5 %.
A two-step amplification protocol (nested PCR) included a
pre-amplification step with outer PCR primers followed by re-
amplification of diluted amplicons by using fusion primers
with inner template specific sequences (Table 1). Pre-
amplification was carried out in 25-μL reactions that
contained 50 ng of cell line DNA or a variable quantity (50–
250 ng) of DNA from FFPE samples, 1.5 mM MgCl2,
200 mM dNTP, 500 nM primers and 1 unit Phusion Hot
Start Flex DNA polymerase (New England Biolabs,
Ipswich, USA). An amplification programme was started by
an initial activation of the enzyme at 98 °C for 30 s. The initial
amplification cycle was denaturation at 98 °C for 10 s, anneal-
ing at 72 °C for 30 s and elongation at 72 °C for 30 s.
Amplification was continued for ten cycles, reducing the
annealing temperature by 1 °C each cycle, followed by 40
cycles of 10 s denaturation at 98 °C, 30 s annealing at 62 °C
and 30 s elongation at 72 °C. PCR products were diluted 1:106
or 1:103 for EGFR or KRAS amplicons, respectively, and
Table 1 Sequences of the PCR
primers for two-step amplifica-
tion protocol and 454 deep
sequencing
F PCR forward, R PCR reverse
aTemplate-specific portion of
each amplicon is shown. Given
additional auxiliary 35-mer
sequences at both ends, real
amplicon size is 70-bp longer
bThe complete PCR primer se-
quence includes an additional
35-mer portion at 5´-end. It
serves for binding to the DNA
capture beads and annealing the
emPCR amplification primers
and the sequencing primer. Ad-
ditionally, it contains the se-
quencing tetranucleotide key
and 10-mer multiple identifier
(MID) for demultiplexing reads.
A total of 12 MIDs (MID1–12)
were used from the 454 Standard
MID set
Primer ID Primer sequences (5´-3´) Amplicon length, bpa
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Fig. 1 Comparative analysis of sensitivity of 454 deep sequencing and
Sanger sequencing by using dilution series of mutant EGFR and KRAS
variants in wild-type DNA from cell lines. Analysis of mutation
frequencies in artificial dilutions of DNA from cell lines with known
mutations (estimated mutation frequency, leftmost percentages) in
EGFR (E746_A750del, T790M and L858R) and KRAS (G13D and
Q61H) by Sanger sequencing (chromatograms) and 454 sequencing
(allele frequency (AF)). Reference sequence and positions of
corresponding mutations are shown, with asterisks indicating the re-
spective changes in the chromatograms. While mutations were reliably
detected by 454 deep sequencing in all dilutions, these were no more
detectable by Sanger sequencing at allele frequencies <10–20 %. No-
tably, NSCLC cell lines with EGFR mutations (E746_A750del,
T790M and L858R) displayed a low level amplification of the mutated
allele, with observed allele frequencies of ~65 % in the undiluted DNA
Table 2 Characteristics of two-step amplification protocol and 454 deep sequencing assay for detection of EGFR and KRAS mutations
Sensitivity and linearity of PCR amplification
Dilution E746_A750del T790M L858R G13D Q61H
50 % 65.3 % 68.6 % 65.5 % 52.3 % 50.5 %
10 % 20.7 % 25.6 % 20.8 % 6.7 % 11.2 %
7.5 % 15.1 % 18.9 % 20.3 % 4.4 % 6.2 %
5 % 11.7 % 12.8 % 11.6 % 2.7 % 5.9 %
2.5 % 8.0 % 9.0 % 5.4 % 0.7 % 3.0 %
1 % 3.0 % 5.0 % 2.5 % 0.2 % 0.5 %
0.5 % 1.5 % 0.8 % 1.0 % 0 % 0 %
R2 0.995 0.990 0.994 0.998 0.996
Reproducibility
E746_A750del T790M L858R G13D Q61H
Mean AF 66.0 % 70.9 % 64.4 % 51.1 % 100.0 %
Std. dev. 1.5 % 1.6 % 1.0 % 2.1 % 0.0 %
Specificity
Exon 18 Exon 19 Exon 20 Exon 21 Exon 2 Exon 3
With homopolymer stretches
99.9 % 1.1 % 2.4 % 2.4 % 2.5 % 0.8 % 0.6 %
After exclusion of homopolymer stretches
99.9 % 0.6 % 0.8 % 0.6 % 0.7 % 0.7 % 0.4 %
AF allele frequency, Std. dev. standard deviation
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employed for re-amplification reaction. It was started by an
initial activation of the enzyme at 98 °C for 30 s. Each
amplification cycle included denaturation at 98 °C for 20 s,
annealing and elongation at 72 °C for 40 s. This procedure
was continued for 40 cycles. Negative control PCR reactions
supplemented with equal amount of water instead of DNA
were included for each amplicon on the same PCR plate.
About 10 μL of each reaction was examined on 3 % agarose
gels. Amplicons were purified by using Agencourt AMPure
XP kit (Beckman Coulter, Beverly, USA), quantified by fluo-
rometry in triplicates using the Quant-iT PicoGreen dsDNA
Assay kit (Invitrogen) and Synergy 2 Multi-Mode Microplate
Reader (Biotek) as directed by the manufacturers. Finally, the
library was pooled in equimolar ratios, and the concentration
was adjusted to 107 molecules/microlitre.
Analysis by deep sequencing
Deep sequencing was performed using the GS Junior
Titanium chemistry according to the standard protocols of
Roche (Basel, Switzerland). A total of ~500,000 beads were
loaded on the picotiter plate yielding a total of 101,109 high-
quality reads per run on average and average coverage of
1,451 reads/amplicon. All reads were processed, aligned to
the human reference sequences of EGFR and KRAS and
analysed for mutation frequencies by using the Amplicon
Variant Analyser software v. 2.5 from Roche.
Sanger sequencing
EGFR and KRAS PCR products for direct sequencing with
Sanger chemistry were amplified in 50 μL reactions that
contained 50 ng cell line DNA or about 100–250 ng DNA
isolated from FFPE tissue, 1.5 mM MgCl2, 200 mM dNTP,
500 nM primers and 2.5 units Taq Polymerase S (Genaxxon
BioScience GmbH, Ulm, Germany). Initial denaturation
step was 94 °C for 3 min. Each amplification cycle included
denaturation at 94 °C for 30 s, annealing at 70 °C for 30 s
and elongation at 72 °C for 40 s. This process was continued
for ten cycles, reducing the annealing temperature by 1 °C
Fig. 2 Demonstration of linear
PCR amplification and
evaluation of reproducibility of
EGFR and KRAS mutation
detection using a novel two-
step amplification and 454 deep
sequencing. a–e Demonstration
of linear PCR amplification in
artificial dilutions of DNA from
cell lines with known mutations
in EGFR (a E746_A750del, b
T790M, c L858R) and KRAS (d
G13D, e Q61H) by 454
sequencing (allele frequency
(AF)). f Allele frequencies of
known EGFR and KRASmutant
variants (x-axis) analysed from
cell line DNA in sixfold




mutation type or its localisation.
Note the low-level
amplification of mutated alleles
in lung cancer cell lines with
EGFR mutations
(E746_A750del, T790M,
L858R) as well as homozygous
status of another lung cancer
cell line with KRAS mutation
(Q61H)
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each cycle, followed by 30 cycles of 30 s denaturation at
94 °C, 30 s annealing at 60 °C and 40 s elongation at 72 °C.
The amplicons were purified with the QIAquick PCR
Purification kit (Qiagen) and sequenced bidirectionally at
an external facility (Seqlab–Sequence Laboratories
Göttingen GmbH, Göttingen, Germany). The sequencing
data were visualised using the FinchTV 1.4.0 software
(Geospiza, Inc., Seattle, USA; http://www.geospiza.com).
The sequences of the PCR and sequencing primers
employed are listed in Supplementary Table S1.
Results
Novel 454 sequencing assay exhibits high sensitivity,
reproducibility and specificity of EGFR and KRAS mutation
detection
Sensitivity
To determine the sensitivity of our novel two-step amplifica-
tion protocol and to confirm unbiased (linear) PCR amplifi-
cation of mutant alleles, a dilution series of cell line DNAs
with knownmutant variants in wild-type DNAwas employed,
with defined mutant allele frequencies of 50 %, 10 %, 7.5 %,
5 %, 2.5 %, 1 % and 0.5 %. DNA aliquots were individually
amplified and analysed by 454 deep sequencing and Sanger
sequencing (Fig. 1). While expected EGFR and KRAS muta-
tions were reliably detected by our assay down to 0.5 % and
1 % estimated mutation frequency, respectively, they were no
more detectable by Sanger chemistry at allele frequencies of
≤10–20 % (Fig. 1). Notably, low-level amplification of the
three mutant EGFR alleles was reproducibly detected in un-
d i lu ted DNA from both ce l l l ines NCI-H1650
(E746_A750del) and NCI-H1975 (T790M and L858R), with
allele frequencies of 65.3 %, 68.6 % and 65.5 %, respectively,
as opposed to an expected value of 50 % for heterozygous
variants (Table 2). Accordingly, observed allele frequencies in
the 0.5 % dilution step were similarly increased, with 1.5 %,
0.8 % and 1.0 %. Regression analysis of allele frequencies
determined by 454 sequencing revealed linear amplification
by our novel amplification protocol, with regression coeffi-
cients R2>0.99 (Fig. 2a–e; Table 2).
Reproducibility
To ascertain reproducibility of mutation quantification by
our deep sequencing assay, we performed sequencing anal-
ysis of each of the mutated cell lines in six analytical
replicates (individual PCR amplification reactions). For
Fig. 3 Evaluation of specificity and background levels of EGFR and
KRAS mutation detection using a novel two-step amplification and 454
deep sequencing. a Background level of unspecific variants for EGFR
exon 18 as determined by 454 sequencing of sixfold DNA replicates
from EGFR wild-type cell line that were separately amplified by PCR.
b Note the higher allele frequency of background variants due to base-
calling errors of 454 pyrosequencing chemistry at positions
c.2137_2141 with a homopolymer stretch of five adenosines.
c Probability density estimation of the background variants was con-
ducted using the Gaussian algorithm as implemented in the function
density in the R statistical software (R Development Core Team 2012).
The 99.9 % specificity values were calculated using the quantile
function of R for all variants before (grey line) and after (black line)
exclusion of homopolymer stretches, with background allele frequen-
cies of 1.1 % and 0.6 %, respectively
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different mutations, mean allele frequencies of 51.1–100 %
with standard deviations of 0–2.1 % were observed
(Table 2), with no significant difference regarding mutation
type (deletion vs. missense mutation) or localisation along
the gene (e.g. EGFR exon 20 vs. exon 21; Fig. 2f).
Specificity
The unique possibility to detect very low allele frequencies
of EGFR and KRAS mutations raises the question of con-
sidering technical errors (background) as low-frequency
variants. To determine the background level or “noise”,
represented by the occurrence of unexpected variants (single
nucleotide changes), we deep-sequenced cell line DNA for
each amplicon in six analytical replicates (individual PCR
amplification reactions), and postulated that variants which
deviate from the reference sequence and occur at very low
allele frequencies are more likely to be artefacts—e.g. DNA
polymerase or base-calling errors—than true biological var-
iants. Indeed, we observed background variants at low fre-
quencies which were unequally distributed among each
amplicon (Fig. 3a). There were “hotspots” with clearly
higher frequency of artefacts, and these were located at
stretches of homopolymers (e.g. single base insertions at
EGFR exon 18 cDNA positions c.2137_2141 corresponding
to a homopolymer stretch of five adenosines; Fig. 3b). A
total of 99.9 % of all background variants (99.9 % specific-
ity) were present at an allele frequency below 0.8–2.5 %,
while this threshold could be reduced down to 0.4–0.8 %
after exclusion of variants associated with homopolymer
stretches (Fig. 3c; Table 2).
Higher sensitivity of EGFR mutation detection in clinical
NSCLC samples using the novel two-step amplification
protocol and 454 deep sequencing compared to Sanger
sequencing
We next applied our novel two-step amplification protocol to
analyse EGFR and KRAS mutations in 21 NSCLC samples
available as FFPE tissue. Five NSCLC specimens with high
tumour cell content >40 % were included that harboured
different EGFR mutations previously detected by Sanger se-
quencing (cases 8–12), while the other 16 specimens with a
tumour cell content of ≤40 % were wild type for EGFR
according to previous Sanger sequencing (Table 3). The sam-
ples included cell block preparations derived from pleural
effusions (n=4) or fine needle aspirations (n=3), small endo-
scopic bronchial biopsies and core needle biopsies (n=11) and
resection specimens (n=3). The DNA of all samples was
amplified using our two-step amplification protocol and ana-
lysed for EGFR andKRASmutations by 454 deep sequencing.
Remarkably, nine unequivocal EGFR mutations with
clinical implications were observed in seven cases with
tumour cell contents of 5–30 %, with allele frequencies
ranging from 0.9–10 % (Table 3; cases 1–7). The mutations
included six missense mutations and three deletions at typ-
ical positions, with two cases harbouring two mutations
each. The critical re-evaluation of the initial Sanger se-
quencing results confirmed that these mutations were not
reliably detectable in the respective chromatograms (Fig. 4).
Five other samples harboured KRAS mutations at allele
frequencies of 1.4–30.5 % (cases 13–17) while the remain-
ing four samples with tumour cell contents of 30–35 % were
of wild type status for EGFR and KRAS (cases 18–21).
Notably, eight of 12 samples with EGFR mutations dis-
played a micropapillary, papillary or lepidic growth pattern
or a combination thereof (Fig. 4) while four of the five
samples with KRAS mutations were of acinar growth pat-
tern. The comparison of tumour cell content vs. observed
allele frequency revealed a significant correlation (R2=
0.898; Fig. 4l).
Discussion
Systematic evaluation of sensitivity, specificity
and reproducibility of EGFR and KRAS mutation detection
by the developed 454 deep sequencing assay
In the current study, we established a novel deep sequencing
assay for detection of clinically relevant EGFR and KRAS
mutant variants, which is especially feasible for poor quality
DNA from FFPE tissue. A key feature of the assay—a two-
step PCR-amplification protocol for amplicon library prep-
aration—enables a substantial increase in the number of
FFPE specimens which can be efficiently processed for
detection of EGFR and KRAS mutations. Systematic analy-
sis of its performance was evaluated using artificial dilutions
of mutant EGFR and KRAS alleles in bulk of wild-type cell
line DNA. We confirmed linear amplification of mutant
alleles with regression coefficients >0.99. The assay was
able to detect as little as 0.2–1.5 % mutation, an enormous
increase in sensitivity compared to Sanger sequencing with
a lower detection limit of 10–20 %. To identify the limit of
reliable detection, specificity of the assay was studied by
considering unexpected variants when sequencing wild-type
DNA as technical errors (background). The background is
an integral measure of errors that are introduced by DNA
polymerase and base-calling process. Dependent on the
different amplicons, 99.9 % of background variants oc-
curred with a frequency below 0.6–2.4 %. Notably, errors
were unequally distributed along the sequence, with “hot-
spots” associated with homopolymer stretches, the known
issue of pyrosequencing chemistry [11]. Exclusion of
homopolymer-associated errors resulted in 99.9 % specific-
ity of 0.4–0.8 %. Thus, we conclude that our assay can
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reliably detect EGFR and KRAS mutations down to at least
1 % allele frequency, whereas background variants occur at
a maximal frequency of 0.8 %. Finally, high reproducibility
of mutant variant detection was achieved with a mean
standard deviation of 0–2.1 %. Taken together, our results
demonstrate highest sensitivity, specificity and reproducibil-
ity of quantitative detection of EGFR and KRAS mutations
by 454 deep sequencing.
Fig. 4 Representative examples of the higher sensitivity of EGFR
mutation detection by 454 deep sequencing compared to Sanger se-
quencing in clinical NSCLC samples with low tumour cell content. a–c
Case 2. Cell block preparation from pleural effusion specimen with
micropapillary growth pattern and low tumour cell content of 5 % (a)
and EGFR exon 19 deletion p.E746_A750del detected with 454 deep
sequencing at allele frequency of 1.6 % (b), compared to false-negative
wild type sequence with Sanger sequencing (c). The corresponding
region in the chromatogram is indicated with asterisks. d–f Case 3.
Cell block preparation from fine needle aspiration specimen with
micropapillary growth pattern and low tumour cell content of 10 %
(d) and EGFR exon 19 deletion p.L747_T751del detected with 454
deep sequencing at allele frequency of 4.3 % (e), which cannot be
reliably detected with Sanger sequencing (f). g–i Case 11. Resection
specimen with lepidic growth pattern and high tumour cell content of
70 % (g), and EGFR exon 19 deletion p.E746_A750del detectable both
with 454 deep sequencing at allele frequency of 43.3 % (h) and with
Sanger sequencing (i). j, k Case 17. Resection specimen with mucin-
producing acinar growth pattern and high tumour cell content of 40 %
(j), and KRAS exon 3 missense mutation p.Q61R detectable by 454
deep sequencing at allele frequency of 30.5 % (k). l Significant corre-
lation of tumour cell content (x-axis) and observed allele frequency
(AF, y-axis) in 17 NSCLC specimens with EGFR and KRAS mutations
determined by 454 deep sequencing (R2=0.898)
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Higher sensitivity of 454 deep sequencing compared
to Sanger sequencing in FFPE NSCLC samples: clinical
implications for stratification of TKI therapy
In a recent study, it has been demonstrated that Sanger
sequencing has a lower threshold of ≤40 % tumour cell
content for reliable detection of EGFR mutations in clinical
NSCLC specimens [10]. Notably, ~30 % of NSCLC sam-
ples in that large series contained ≤40 % tumour cells and
were therefore non-informative for EGFR mutation status.
This issue is particularly relevant for patients with extensive
disease (stage IV), where frequently only small biopsies or
even cytological preparations from pleural effusions are
available, and non-informative EGFR mutation analysis will
lead to re-biopsy with additional risk for the patient as well
as additional costs for the clinic. Moreover, a false-negative
EGFR mutation analysis due to low tumour cell content will
delay or even preclude targeted therapy with TKI in these
patients, with potentially negative impact on survival.
Therefore, we aimed to demonstrate the significant impact
of higher sensitivity of the developed 454 deep sequencing
assays compared to Sanger sequencing in 16 clinical
NSCLC samples with EGFR wild type status according to
Sanger sequencing and low tumour cell content ≤40 %.
Remarkably, we observed seven cases that harboured clini-
cally relevant EGFR mutations at allele frequencies of 0.9–
10 %, which were not detectable by Sanger sequencing.
Five other cases displayed KRAS mutations, and four sam-
ples were of wild type status for both genes. In the control
set of five samples with tumour cell contents of >40 %,
EGFR mutations were detectable both with 454 deep se-
quencing and Sanger sequencing. This observation is con-
cordant with an earlier study which concludes that NSCLC
samples with a tumour cell content of ≤40 % cannot be
reliably analysed by Sanger sequencing given unacceptably
high probability of false-negative reports [10]. In contrast to
another study [11], we found a clear correlation between the
tumour cell content and the observed allele frequency of
mutations analysed by 454 deep sequencing, and this obser-
vation further emphasizes the need of a careful evaluation of
the tumour cell content in clinical samples before choosing
the adequate technique for molecular analysis. Of note, the
quantification of the tumour cell content in the samples
further helps to interpret the clinical relevance of mutations
found at low allele frequencies. In samples with low tumour
cell content, a concurring low allele frequency of a mutation
likely reflects the large amount of non-neoplastic cells with
wild-type alleles, comparable to the artificial dilution series
of cell line DNA employed in this study. Accordingly, the
authors suggest that these tumours should be regarded and
treated similar to those tumours with high tumour cell con-
tent, where mutations can be detected with less sensitive
techniques (e.g. Sanger sequencing). In contrast, the high
sensitivity of deep sequencing will also identify variants at
low allele frequencies in samples with high tumour cell
content, and the biological and therapeutic consequences
of these findings are less clear. Until further ongoing studies
will clarify this important question, these cases should be
discussed together with the clinician, and if a targeted ther-
apy with TKI is administered, it might be helpful to closely
monitor the therapy effect in these patients.
Notably, there was also a higher prevalence of EGFR
mutations in NSCLC samples with predominant micropapil-
lary, papillary or lepidic growth pattern while KRAS muta-
tions were restricted to tumours with acinar or solid growth
pattern [14]. These different phenotypes in molecularly de-
fined subgroups are increasingly recognized in different
tumour entities and underline the impact of critical interpre-
tation of genetic results in the context of clinicopathological
characteristics. Thus, it should be emphasized that reporting
of a wild-type genotype in NSCLC specimens displaying
one of the characteristic EGFR phenotypes should alert to
the possibility of false-negative results and the need for
more sensitive analytical methods. In contrast, a tumour
with acinar or solid growth pattern in combination with
the finding of an unusual mutation at low allele frequency
in a sample with high tumour cell content may indicate less
responsiveness to TKI therapy.
While the much higher sensitivity of deep sequencing in
clinical NSCLC samples is clearly demonstrated in the
publication by Thomas and colleagues [11] and also in the
current study, reagent costs and time for sample preparation
are also critical factors for diagnostic molecular pathology
laboratories in daily routine diagnostics and may influence
the decision which technique is used. In direct comparison
to Sanger sequencing, the reagent costs for this assay are
two- to threefold higher, and the time for sample preparation
is more labour intensive. Thus, only in samples with low
tumour cell content ≤40 %, the advantage of higher sensi-
tivity outweighs the higher costs and longer time of deep
sequencing at the current stage. However, the predictable
need for simultaneous analysis of multiple genetic aberra-
tions within one sample (e.g. mutation analysis of BRAF,
PI3K, MEK1, HER2) [7] in the near future will likely shift
this balance to next generation parallel sequencing methods,
as reagent costs and time for sample preparation will be less
important when larger gene panels are analysed.
In conclusion, our protocol reliably and specifically detects
EGFR and KRAS mutations present at allele frequencies as
low as 1 % while 99.9 % of the background variants in non-
homopolymer regions occur at allele frequencies <0.8 %.
Therefore, this assay is superior to Sanger sequencing with
dramatically increased sensitivity, and can be applied to
NSCLC specimens independent of the tumour cell content
or tumour cell amount (small endoscopic biopsies, core needle
biopsies, cell block preparations from pleural effusions).
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Regarding the dramatic consequences of a false-negative
EGFRmutation analysis, NSCLC samples with a low tumour
cell content ≤40 % cannot be reliably analysed by Sanger
sequencing, and especially in these cases the increased sensi-
tivity of deep sequencing will outweight its higher costs and
longer sample preparation time. As flexibility of 454 deep
sequencing easily allows the inclusion of further DNA-based
predictive targets, simultaneous multi-gene panel testing for
optimised therapy-related stratification of NSCLC patients
can be envisioned in the near future and will help to establish
454 deep sequencing or similar next generation parallel se-
quencing methods in daily routine diagnostics.
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